Clinical Trials Logo

Primary Sclerosing Cholangitis clinical trials

View clinical trials related to Primary Sclerosing Cholangitis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05866809 Completed - Clinical trials for Primary Sclerosing Cholangitis

Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis

Start date: October 28, 2021
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the improvement of bile duct strictures following the administration of HK-660S in patients with Primary Sclerosing Cholangitis(PSC). Percentage of subjects who show improvement of severity of PSC as assessed by Magnetic Resonance Cholangiopancreatography(MRCP) at Week 12 from baseline, with improvement defined as a decrease of -1 or more in the MRCP and change of alkaline phosphatase(ALP) level will be assessed at Week 12 from baseline.

NCT ID: NCT04480840 Completed - Clinical trials for Primary Sclerosing Cholangitis

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

Start date: July 27, 2020
Phase: Phase 2
Study type: Interventional

A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis

NCT ID: NCT04024813 Completed - Clinical trials for Primary Sclerosing Cholangitis

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

Start date: November 12, 2019
Phase: Phase 2
Study type: Interventional

The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).

NCT ID: NCT03809559 Completed - Liver Diseases Clinical Trials

Repeatability and Reproducibility of Quantitative MRCP

Start date: July 19, 2018
Phase:
Study type: Observational

This study aims to determine the repeatability and reproducibility of Quantitative Magnetic Resonance Cholangiopancreatography (MRCP). Imaging scientists at Perspectum Diagnostics have developed a hessian-based mathematical model to enhance conventional MRCP to a 3D geometric model of the biliary tree, 'Quantitative MRCP'. This enables advanced quantitative measurement of bile duct width, orientation, branching point and curvative metrics. The technology has been validated against 3D printed phantoms for accuracy, and early clinical research has demonstrated the technology has potential for clinical impact, with improvement in radiologist performance versus conventional non-enhanced MRCP imaging (Vikal et al 2017). Quantitative MRCP aims to act as a tool to not only improve assessment of the current status of the biliary tree, but also act as a mechanism to track change within the ducts. Thus, it must be established that any change between scans is due to change in the physiology of the individual and not due to a quirk or fault of the technology. In order to achieve this a series of scans will be performed on an individual over a short period of time, for which the condition of the biliary tree within that individual can be assumed to be constant. Between each scan, subject and coil repositioning will occur. The study will recruit a group of adult volunteers, from both diseased groups and healthy groups in order to achieve a range of physiological biliary metrics.

NCT ID: NCT03722576 Completed - Clinical trials for Primary Sclerosing Cholangitis

Vidofludimus Calcium for Primary Sclerosing Cholangitis

PSC
Start date: June 17, 2019
Phase: Phase 2
Study type: Interventional

To examine the safety, tolerability, and efficacy of daily dosing with vidofludimus calcium over a 6-month period.

NCT ID: NCT03099603 Completed - Clinical trials for Primary Sclerosing Cholangitis

A Study of HTD1801 in Healthy Subjects

Start date: March 24, 2017
Phase: Phase 1
Study type: Interventional

This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.

NCT ID: NCT03069976 Completed - Clinical trials for Primary Sclerosing Cholangitis

"Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children"

Start date: January 2016
Phase: N/A
Study type: Interventional

Based upon the possible implication of microbiota and abnormal microbial metabolites such as altered bile acids, in the pathogenesis of PSC, emerging data suggests that oral antibiotics, such as vancomycin and metronidazole, may have therapeutic effects in this overlap syndrome or PSC. The goal of our study is to evaluate role of antibiotics and microflora in children with AIH/PSC overlap syndrome or with PSC alone. The investigators hope to learn what effects oral antibiotics has on the bacteria present in stool, and hope to learn to characterize human intestinal microbial communities, in children suffering from overlap syndrome or PSC. The hypothesis of the investigators is that overlap syndrome and PSC develop due to altered microflora and the resulting abnormal bile acids pool. The outcome of overlap syndrome or PSC could be affected by presence or absence of RCUH. Antibiotics to correct the microflora may result in disease/cholangiopathy remission.

NCT ID: NCT03041662 Completed - Cholangiocarcinoma Clinical Trials

Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)

PSC
Start date: October 31, 2011
Phase:
Study type: Observational

This observational study of a national cohort of 600 Swedish PSC patients include yearly MR/MRCP, biobanking of serum, plasma and blood, followup clinical data (interventions, symptoms, labs, colonoscopy). The aim is to collect a well characterized cohort of PSC patients and provide future possibilities to evaluate biomarkers for prognosis and early cancer detection.

NCT ID: NCT02978339 Completed - Clinical trials for Primary Sclerosing Cholangitis

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

Start date: June 9, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether curcumin, a drug and naturally-occurring plant compound, is safe and effective in the treatment of primary sclerosing cholangitis (PSC).

NCT ID: NCT02943460 Completed - Clinical trials for Primary Sclerosing Cholangitis

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Start date: November 29, 2016
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of cilofexor in adults with primary sclerosing cholangitis (PSC).